Formycon AG (ETR:FYB)

Market Cap	524.41M
Revenue (ttm)	60.80M
Net Income (ttm)	63.90M
Shares Out	17.66M
EPS (ttm)	3.83
PE Ratio	7.76
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	58,706
Average Volume	66,705
Open	30.70
Previous Close	30.50
Day's Range	29.30 - 31.15
52-Week Range	27.55 - 64.40
Beta	0.81
RSI	16.36
Earnings Date	Mar 27, 2025

About Formycon AG

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names. The company’s pipeline includes FYB202, a biosimilar candidate for Stelara used in ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 238
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: FYB

Financial Performance

In 2023, Formycon AG's revenue was 77.70 million, an increase of 82.83% compared to the previous year's 42.50 million. Earnings were 75.80 million, an increase of 110.59%.